Home-based transcranial photobiomodulation improves cognitive function in mild cognitive impairment due to Alzheimer's disease: A randomized, double-blind, placebo-controlled confirmatory trial
Journal of Alzheimer’s Disease · 2026
DOI: 10.1177/13872877261443973 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Alzheimer’s Disease, 2026. Verfasst von Hyelim Chun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials Center, Gangnam St Peter's General Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction, Low-Level Light Therapy, Cognition. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Y&J Bio.
Themen: Demenz
Abstract (Originalsprache)
Background
Alzheimer's disease (AD) is a progressive neurodegenerative disorder in which early bioenergetic dysfunction is increasingly implicated in its pathogenesis. Transcranial photobiomodulation (tPBM), a non-invasive neuromodulation using near-infrared light, has shown promise in improving cerebral metabolism and cognitive function.
Objective
To assess the safety and efficacy of a home-administered tPBM intervention in individuals with mild cognitive impairment (MCI) due to AD.
Methods
In this randomized clinical trial, 80 participants meeting the NIA-AA criteria for MCI due to AD were recruited. Participants self-administered a tPBM device emitting 808 nm near-infrared light over the bilateral dorsolateral prefrontal cortex, six times weekly for 12 weeks. The primary outcome was the change in MoCA-K score from baseline to week 13. Secondary outcomes included K-MMSE2, CERAD-K, and GDepS scores.
Results
Active tPBM significantly improved cognitive performance compared with the placebo. Mean MoCA-K scores increased by 3.87 ± 2.51 points in the active group versus a 0.74 ± 2.85 point decline in the placebo group (p < 0.001). K-MMSE2 scores improved significantly (p < 0.001). CERAD-K showed a significant between-group difference at week 13 (p < 0.001), while GDepS scores remained unchanged. No device-related adverse events occurred, and adherence to home-based treatment was high.
Conclusions
12 weeks of home-administered tPBM safely and significantly improved cognitive function in individuals with MCI due to AD. The observed benefits are consistent with enhanced mitochondrial metabolism, cerebral perfusion, and synaptic efficiency. These findings support tPBM as a promising, non-pharmacological treatment for MCI due to AD and as a preventative strategy against AD. Trial Registration Korean Clinical Research Information Service (CRiS), https://cris.nih.go.kr , KCT0011155.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Trials Center, Gangnam St Peter's General Hospital, Seoul, Republic of Korea.
- Department of Rehabilitation Medicine, Gangnam St Peter's General Hospital, Seoul, Republic of Korea.
- Department of Neurology, Gangnam St Peter's General Hospital, Seoul, Republic of Korea.
- Department of Neurosurgery, Gangnam St Peter's General Hospital, Seoul, Republic of Korea.
ORCID-Profile: Hyelim Chun, Hee Won Lee, Seung Bong Hong, Sang Soo Ha, Kang Jun Yoon
Förderung
- Y&J Bio
Zitieren
APA
Chun, H., Lee, H. W., Hong, S. B., Ha, S. S., & Yoon, K. J. (2026). Home-based transcranial photobiomodulation improves cognitive function in mild cognitive impairment due to Alzheimer's disease: A randomized, double-blind, placebo-controlled confirmatory trial. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877261443973
Vancouver
Chun H, Lee HW, Hong SB, Ha SS, Yoon KJ. Home-based transcranial photobiomodulation improves cognitive function in mild cognitive impairment due to Alzheimer's disease: A randomized, double-blind, placebo-controlled confirmatory trial. Journal of Alzheimer’s Disease. 2026. doi:10.1177/13872877261443973
BibTeX
@article{Chun2026,
author = {Chun, Hyelim and Lee, Hee Won and Hong, Seung Bong and Ha, Sang Soo and Yoon, Kang Jun},
title = {Home-based transcranial photobiomodulation improves cognitive function in mild cognitive impairment due to Alzheimer's disease: A randomized, double-blind, placebo-controlled confirmatory trial},
journal = {Journal of Alzheimer’s Disease},
year = {2026},
doi = {10.1177/13872877261443973}
}
EUVIMED